Comment
. 2010 May 5;303(17):1698; author reply 1698.
doi: 10.1001/jama.2010.522.
Composite end points in clinical trials
- PMID: 20442384
- DOI: 10.1001/jama.2010.522
Item in Clipboard
Comment
Composite end points in clinical trials
JAMA.
.
No abstract available
Comment on
-
Composite end points in randomized trials: there is no free lunch.JAMA. 2010 Jan 20;303(3):267-8. doi: 10.1001/jama.2009.2017. JAMA. 2010. PMID: 20085955 No abstract available.
Similar articles
-
Composite end points in randomized trials: there is no free lunch.JAMA. 2010 Jan 20;303(3):267-8. doi: 10.1001/jama.2009.2017. JAMA. 2010. PMID: 20085955 No abstract available.
-
Ensuring integrity in industry-sponsored research: primum non nocere, revisited.JAMA. 2010 Mar 24;303(12):1196-8. doi: 10.1001/jama.2010.337. JAMA. 2010. PMID: 20332409 No abstract available.
-
Seeking alternatives to Hard End Points: is imaging the best APPROACH?Circulation. 2010 Mar 16;121(10):1165-8. doi: 10.1161/CIR.0b013e3181d83b4f. Epub 2010 Mar 1. Circulation. 2010. PMID: 20194886 No abstract available.
-
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?BMJ. 2005 Oct 8;331(7520):836-8. doi: 10.1136/bmj.331.7520.836. BMJ. 2005. PMID: 16210286 Free PMC article. Review.
-
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.Diabet Med. 2015 Mar;32(3):305-13. doi: 10.1111/dme.12627. Epub 2014 Dec 3. Diabet Med. 2015. PMID: 25472014 Review.
Cited by
-
Misspecification of Cox regression models with composite endpoints.Stat Med. 2012 Dec 10;31(28):3545-62. doi: 10.1002/sim.5436. Epub 2012 Jun 27. Stat Med. 2012. PMID: 22736519 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
